Regeneron Retained Earnings vs Deferred Long Term Liab Analysis

REGN Stock

USD 890.68 15.86 1.75%

Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Retained Earnings and its Deferred Long Term Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Retained Earnings vs Deferred Long Term Liab

Retained Earnings vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Retained Earnings account and Deferred Long Term Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Regeneron Pharmaceuticals' Retained Earnings and Deferred Long Term Liab is 0.59. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Retained Earnings and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Regeneron Pharmaceuticals are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Retained Earnings i.e., Regeneron Pharmaceuticals' Retained Earnings and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 27th of April 2024, Tax Provision is likely to grow to about 584.1 M, while Sales General And Administrative To Revenue is likely to drop 0.26.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	4.7B	5.6B	7.1B	7.4B
Cost Of Revenue	2.4B	1.6B	883.7M	927.9M

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Accounts Payable	Short Term Debt	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab
Total Assets		0.97	1.0	0.94	-0.06	0.99	0.97	0.93	-0.24	0.96	0.98	0.15	0.95	0.32	-0.66	0.97	0.98	0.83	0.93	0.94	0.98	0.58	0.99	0.93	0.98	0.58
Total Current Liabilities	0.97		0.96	0.94	-0.03	0.95	0.99	0.84	-0.31	0.98	0.98	0.2	0.95	0.45	-0.66	0.99	0.99	0.73	0.96	0.88	0.99	0.65	0.97	0.83	0.98	0.56
Total Stockholder Equity	1.0	0.96		0.93	-0.09	0.99	0.95	0.94	-0.25	0.95	0.96	0.13	0.92	0.28	-0.67	0.95	0.97	0.85	0.91	0.96	0.96	0.55	0.99	0.94	0.97	0.56
Property Plant And Equipment Net	0.94	0.94	0.93		-0.16	0.89	0.93	0.87	-0.15	0.91	0.94	0.31	0.96	0.37	-0.44	0.96	0.93	0.68	0.86	0.83	0.95	0.67	0.97	0.81	0.96	0.78
Net Debt	-0.06	-0.03	-0.09	-0.16		0.0	-0.1	-0.01	0.13	-0.14	-0.01	-0.17	0.08	-0.04	-0.49	0.02	-0.09	0.03	0.22	-0.16	-0.08	-0.04	-0.1	0.01	-0.06	-0.4
Retained Earnings	0.99	0.95	0.99	0.89	0.0		0.94	0.93	-0.26	0.95	0.96	0.05	0.91	0.27	-0.75	0.95	0.97	0.87	0.93	0.96	0.95	0.53	0.97	0.95	0.96	0.48
Cash	0.97	0.99	0.95	0.93	-0.1	0.94		0.82	-0.3	0.98	0.98	0.23	0.93	0.45	-0.62	0.98	0.99	0.71	0.95	0.88	0.98	0.63	0.95	0.82	0.97	0.54
Non Current Assets Total	0.93	0.84	0.94	0.87	-0.01	0.93	0.82		-0.07	0.8	0.86	0.07	0.88	0.14	-0.62	0.87	0.84	0.9	0.8	0.91	0.86	0.48	0.93	0.98	0.89	0.6
Non Currrent Assets Other	-0.24	-0.31	-0.25	-0.15	0.13	-0.26	-0.3	-0.07		-0.39	-0.2	-0.05	-0.06	-0.37	0.26	-0.19	-0.32	-0.4	-0.26	-0.26	-0.22	0.01	-0.22	-0.15	-0.23	-0.01
Cash And Short Term Investments	0.96	0.98	0.95	0.91	-0.14	0.95	0.98	0.8	-0.39		0.97	0.18	0.89	0.41	-0.63	0.95	0.99	0.73	0.92	0.91	0.97	0.58	0.95	0.82	0.95	0.5
Net Receivables	0.98	0.98	0.96	0.94	-0.01	0.96	0.98	0.86	-0.2	0.97		0.22	0.97	0.33	-0.65	0.99	0.99	0.71	0.96	0.89	0.98	0.62	0.97	0.85	0.97	0.56
Common Stock Shares Outstanding	0.15	0.2	0.13	0.31	-0.17	0.05	0.23	0.07	-0.05	0.18	0.22		0.28	0.27	0.37	0.24	0.19	-0.07	0.17	0.05	0.21	0.23	0.2	-0.02	0.16	0.47
Non Current Liabilities Total	0.95	0.95	0.92	0.96	0.08	0.91	0.93	0.88	-0.06	0.89	0.97	0.28		0.37	-0.59	0.99	0.93	0.67	0.94	0.81	0.96	0.69	0.95	0.83	0.96	0.65
Other Current Assets	0.32	0.45	0.28	0.37	-0.04	0.27	0.45	0.14	-0.37	0.41	0.33	0.27	0.37		-0.13	0.42	0.39	0.12	0.43	0.14	0.45	0.69	0.29	0.12	0.43	0.24
Other Stockholder Equity	-0.66	-0.66	-0.67	-0.44	-0.49	-0.75	-0.62	-0.62	0.26	-0.63	-0.65	0.37	-0.59	-0.13		-0.63	-0.65	-0.71	-0.76	-0.66	-0.61	-0.25	-0.6	-0.71	-0.63	0.11
Total Liab	0.97	0.99	0.95	0.96	0.02	0.95	0.98	0.87	-0.19	0.95	0.99	0.24	0.99	0.42	-0.63		0.97	0.71	0.96	0.86	0.99	0.68	0.97	0.84	0.98	0.61
Total Current Assets	0.98	0.99	0.97	0.93	-0.09	0.97	0.99	0.84	-0.32	0.99	0.99	0.19	0.93	0.39	-0.65	0.97		0.75	0.94	0.91	0.98	0.61	0.97	0.85	0.97	0.53
Intangible Assets	0.83	0.73	0.85	0.68	0.03	0.87	0.71	0.9	-0.4	0.73	0.71	-0.07	0.67	0.12	-0.71	0.71	0.75		0.71	0.87	0.72	0.28	0.81	0.94	0.77	0.37
Short Long Term Debt Total	0.93	0.96	0.91	0.86	0.22	0.93	0.95	0.8	-0.26	0.92	0.96	0.17	0.94	0.43	-0.76	0.96	0.94	0.71		0.81	0.94	0.61	0.91	0.81	0.94	0.4
Other Current Liab	0.94	0.88	0.96	0.83	-0.16	0.96	0.88	0.91	-0.26	0.91	0.89	0.05	0.81	0.14	-0.66	0.86	0.91	0.87	0.81		0.87	0.36	0.93	0.94	0.88	0.47
Accounts Payable	0.98	0.99	0.96	0.95	-0.08	0.95	0.98	0.86	-0.22	0.97	0.98	0.21	0.96	0.45	-0.61	0.99	0.98	0.72	0.94	0.87		0.73	0.97	0.84	0.99	0.59
Short Term Debt	0.58	0.65	0.55	0.67	-0.04	0.53	0.63	0.48	0.01	0.58	0.62	0.23	0.69	0.69	-0.25	0.68	0.61	0.28	0.61	0.36	0.73		0.57	0.41	0.67	0.49
Property Plant And Equipment Gross	0.99	0.97	0.99	0.97	-0.1	0.97	0.95	0.93	-0.22	0.95	0.97	0.2	0.95	0.29	-0.6	0.97	0.97	0.81	0.91	0.93	0.97	0.57		0.91	0.97	0.65
Short Term Investments	0.93	0.83	0.94	0.81	0.01	0.95	0.82	0.98	-0.15	0.82	0.85	-0.02	0.83	0.12	-0.71	0.84	0.85	0.94	0.81	0.94	0.84	0.41	0.91		0.88	0.47
Inventory	0.98	0.98	0.97	0.96	-0.06	0.96	0.97	0.89	-0.23	0.95	0.97	0.16	0.96	0.43	-0.63	0.98	0.97	0.77	0.94	0.88	0.99	0.67	0.97	0.88		0.6
Other Liab	0.58	0.56	0.56	0.78	-0.4	0.48	0.54	0.6	-0.01	0.5	0.56	0.47	0.65	0.24	0.11	0.61	0.53	0.37	0.4	0.47	0.59	0.49	0.65	0.47	0.6

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Total Current Liabilities	1.8B	2.8B	3.5B	3.8B	3.4B	3.6B
Total Stockholder Equity	11.1B	11.0B	18.8B	22.7B	26.0B	27.3B
Property Plant And Equipment Net	2.9B	3.2B	3.5B	3.8B	4.1B	4.4B
Net Debt	(903.9M)	502M	(185.9M)	(404.5M)	(27.1M)	(28.5M)
Retained Earnings	7.4B	10.9B	19.0B	23.3B	27.3B	28.6B
Cash	1.6B	2.2B	2.9B	3.1B	2.7B	2.9B
Non Current Assets Total	4.2B	4.4B	4.9B	7.1B	13.6B	14.3B
Non Currrent Assets Other	531.8M	328.9M	555.2M	(4.7B)	444.1M	466.3M
Cash And Short Term Investments	6.5B	6.7B	12.5B	14.3B	10.8B	11.4B
Net Receivables	2.7B	4.1B	6.0B	5.3B	5.7B	6.0B
Common Stock Shares Outstanding	114.6M	115.1M	112.2M	113.5M	113.7M	75.4M
Liabilities And Stockholders Equity	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Non Current Liabilities Total	1.9B	3.3B	3.2B	2.7B	3.7B	3.9B
Other Current Assets	959.3M	1.2B	332.4M	933M	386.6M	203.9M
Other Stockholder Equity	3.7B	102.9M	(173.4M)	(404M)	(1.2B)	(1.1B)
Total Liab	3.7B	6.1B	6.7B	6.6B	7.1B	7.5B
Total Current Assets	10.6B	12.8B	20.5B	22.1B	19.5B	20.5B
Short Long Term Debt Total	713.9M	2.7B	2.7B	2.7B	2.7B	2.8B
Other Current Liab	781.1M	122.4M	1.7B	2.0B	2.4B	2.5B
Accounts Payable	418.1M	475.5M	564M	589.2M	606.6M	636.9M
Property Plant And Equipment Gross	2.9B	3.2B	4.9B	5.4B	6.1B	6.4B
Accumulated Other Comprehensive Income	21.1M	29.3M	(26.2M)	(238.8M)	(80.9M)	(76.9M)
Short Term Investments	1.6B	1.4B	2.8B	4.6B	8.1B	8.5B
Inventory	1.4B	1.9B	2.0B	2.4B	2.6B	2.7B
Other Liab	889M	635.5M	515.3M	707.8M	814.0M	854.7M
Other Assets	913.3M	2.8B	555.2M	747.6M	859.7M	902.7M
Property Plant Equipment	2.9B	3.2B	3.5B	3.8B	4.3B	4.5B
Current Deferred Revenue	591.7M	577.7M	442M	547.7M	458.9M	481.8M
Net Tangible Assets	11.1B	11.0B	18.8B	21.7B	25.0B	26.3B
Retained Earnings Total Equity	7.4B	10.9B	19.0B	23.3B	26.8B	28.1B
Long Term Debt Total	713.9M	2.0B	2.0B	2.0B	2.3B	2.4B
Capital Surpluse	4.4B	6.7B	8.1B	9.9B	11.4B	12.0B
Long Term Investments	3.3B	3.1B	6.8B	6.6B	5.4B	3.3B

Currently Active Assets on Macroaxis

GM	General Motors
S	SentinelOne
MSFT	Microsoft
C	Citigroup
F	Ford Motor

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Global Correlations Find global opportunities by holding instruments from different markets
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.03)

Earnings Share

34.81

Revenue Per Share

122.935

Quarterly Revenue Growth

0.006

Return On Assets

0.0849

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Retained Earnings vs Deferred Long Term Liab Analysis

Retained Earnings vs Deferred Long Term Liab

Retained Earnings vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Retained Earnings

Deferred Long Term Liab

Regeneron Pharmaceuticals fundamental ratios Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Regeneron Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Current Liabilities

Short Long Term Debt Total	- 0.76	Other Stockholder Equity
Other Stockholder Equity	- 0.75	Retained Earnings
Short Term Investments	- 0.71	Other Stockholder Equity
Intangible Assets	- 0.71	Other Stockholder Equity
Other Stockholder Equity	- 0.67	Total Stockholder Equity
Other Current Liab	- 0.66	Other Stockholder Equity